Neural correlates of affective control regions induced by common therapeutic strategies in major depressive disorders: An activation likelihood estimation meta-analysis study

Neurosci Biobehav Rev. 2022 Jun:137:104643. doi: 10.1016/j.neubiorev.2022.104643. Epub 2022 Mar 30.

Abstract

In major depressive disorder (MDD), not only the pathophysiology of this disease is unknown but also the mechanisms of clinical efficacy across its therapeutic strategies are unclear. Although neuroimaging studies adopted activation likelihood estimation (ALE) approach to identify the convergent abnormalities of human brain in the MDD patients, the common alterations after antidepressant therapies were not summarized. Thus, we extracted the coordinates of brain regions in the MDD patients that showed differences in resting-state function, gray matter morphometry, and task-evoked neuronal responses after therapies. The ALE algorithm (GingerALE2.0.3) was employed in all 53 studies (64 experiments with 1406 MDD patients). Consistent results across treatment therapies were reported in the affective control network, including the bilateral thalamus, bilateral amygdala/parahippocampal gyrus, right anterior cingulate cortex/middle frontal gyrus, and right insular cortex/claustrum. Only electroconvulsive therapy partially replicated above findings. Our results indicate the antidepressant therapies efficiently influence core structures of the affective control network, which might be the underlying mechanism of remission in depression and provides potential targets for further treatment strategies.

Keywords: Activation likelihood estimation; Antidepressant therapies; Major depressive disorder; Neuroimaging.

Publication types

  • Meta-Analysis
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antidepressive Agents / therapeutic use
  • Brain / diagnostic imaging
  • Depressive Disorder, Major* / diagnostic imaging
  • Depressive Disorder, Major* / drug therapy
  • Gray Matter
  • Humans
  • Likelihood Functions
  • Magnetic Resonance Imaging / methods

Substances

  • Antidepressive Agents